Eloxx Pharmaceuticals Dividenden en inkoop

Dividend criteriumcontroles 0/6

Eloxx Pharmaceuticals heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

-162,900,000.0%

Terugkoop Rendement

Totaal aandeelhoudersrendement	-162,900,000.0%
Toekomstig dividendrendement	n/a
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	n/a

Recente updates van dividend en inkoop

Geen updates

Recent updates

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

Jan 13

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van ELOX in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van ELOX zijn gestegen.

Dividendrendement versus markt

Eloxx Pharmaceuticals Dividendrendement versus markt

Hoe verhoudt ELOX dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (ELOX)	n/a
Markt onderkant 25% (US)	1.4%
Markt Top 25% (US)	4.2%
Gemiddelde industrie (Pharmaceuticals)	2.4%
Analist prognose (ELOX) (tot 3 jaar)	n/a

Opmerkelijk dividend: Het dividendrendement van ELOX kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van ELOX kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio ELOX te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat ELOX geen uitbetalingen heeft gerapporteerd.

Eloxx Pharmaceuticals Dividenden en inkoop

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente updates van dividend en inkoop

Recent updates

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Nasdaq to Delist Common Stock of Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals Receives a Determination Letter from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013

New minor risk - Shareholder dilution

Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Nasdaq Grants Extension to Eloxx Pharmaceuticals to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

New major risk - Market cap size

Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Receives Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Elx-02 for the Treatment of Alport Syndrome

Price target increased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives Written Notification Letter from the Listing Qualifications Department of Nasdaq

Eloxx Pharmaceuticals, Inc. Announces Topline Results from the Phase 2 Clinical Trial of ELX-02 in Combination with Ivacaftor in Class 1 Cystic Fibrosis (CF) Patients with At Least One Nonsense Mutation

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Price target decreased to US$2.25

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Price target decreased to US$3.00

Eloxx Pharmaceuticals Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

President exercised options and sold US$59k worth of stock

Price target increased to US$4.03

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

COO, General Counsel & Corporate Secretary Neil Belloff has left the company

Executive Director of Finance & Accounting, Corporate Controller and Treasurer Gary Rakers has left the company

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell 3000E Index

Eloxx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $45.000001 million.

Eloxx Pharmaceuticals EPS misses by $0.06

Independent Director has left the company

CEO & Director Gregory Williams has left the company

Founder & Director Silvia Noiman has left the company

VP of Finance & Accounting, Principal Financial & Accounting Officer and Treasurer has left the company

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Eloxx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 11, 2021

CEO & Director exercised options and sold US$61k worth of stock

New 90-day high: US$4.51

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The Cystic Fibrosis Foundation Awards upto $2 Million to Eloxx Pharmaceuticals Inc. for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

New 90-day high: US$3.94

New 90-day low: US$2.42

Eloxx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$2.68

Eloxx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell Microcap Value Index

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend